|
| Status |
Public on Dec 07, 2016 |
| Title |
staud-00261: LYM169 |
| Sample type |
RNA |
| |
|
| Source name |
diffuse large-B-cell lymphoma
|
| Organism |
Homo sapiens |
| Characteristics |
dlbcl sample (lym number): 169
analysis set: Validation
follow-up (years): 0.7
status at follow-up: Dead
subgroup: Type III
ipi group: Low
germinal center b cell signature: 0.56
lymph node signature: 1.72
proliferation signature: -0.47
bmp6: 0.21
mhc class ii signature: -0.47
outcome predictor score: -0.49
|
| Extracted molecule |
total RNA |
| Extraction protocol |
See mage-tab files linked to series entry for additional details
|
| Label |
Cy5/Cy3
|
| Label protocol |
See mage-tab files linked to series entry for additional details
|
| |
|
| Hybridization protocol |
See mage-tab files linked to series entry for additional details
|
| Scan protocol |
See mage-tab files linked to series entry for additional details
|
| Data processing |
See mage-tab files linked to series entry for additional details
|
| |
|
| Submission date |
Dec 06, 2016 |
| Last update date |
Dec 07, 2016 |
| Contact name |
Mervi Heiskanen |
| E-mail(s) |
mervi.heiskanen@nih.gov
|
| Phone |
2402765175
|
| Organization name |
NCI
|
| Department |
CBIIT
|
| Street address |
9609 Medical Center Drive, 1W378
|
| City |
Rockville |
| State/province |
MD |
| ZIP/Postal code |
20850 |
| Country |
USA |
| |
|
| Platform ID |
GPL22757 |
| Series (1) |
| GSE90953 |
caArray_staud-00261: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma |
|
